11:02 AM EDT, 05/23/2024 (MT Newswires) -- Tango Therapeutics ( TNGX ) said Thursday it has decided to discontinue the development of USP1, or ubiquitin-specific protease 1, inhibitor TNG348 due to liver toxicity observed in patients during a phase 1/2 clinical trial.

Liver function abnormalities were observed in patients who remained in the trial for longer than eight weeks, the company said, adding no patient had received the investigational molecule combined with olaparib. The trial evaluated the safety and efficacy of TNG348 combined with olaparib in patients with BRCA1/2-mutant and other HRD+, or homologous recombination deficient, cancers, Tango Therapeutics ( TNGX ) said.

Tango said its cash runway will extend into 2027, with a focus on its existing portfolio, including the PRMT5 program.

The company's shares were up 3.2% in recent trading.

Price: 7.63, Change: +0.24, Percent Change: +3.22